NeuroSense Therapeutics Shares Are Trading Higher After the Company Announced It Initiated a Process to Seek Early Commercialization Approval for PrimeC in ALS Under Heath Canada's Notice of Compliance With Conditions Policy.
NeuroSense Therapeutics Shares Are Trading Higher After the Company Announced It Initiated a Process to Seek Early Commercialization Approval for PrimeC in ALS Under Heath Canada's Notice of Compliance With Conditions Policy.
NeuroSense Therapeutics股價上漲，因該公司宣佈已啓動尋求在加拿大衛生部根據條件遵從通知政策下，爲PrimeC在ALS早期商業化獲批的過程。
NeuroSense Therapeutics Shares Are Trading Higher After the Company Announced It Initiated a Process to Seek Early Commercialization Approval for PrimeC in ALS Under Heath Canada's Notice of Compliance With Conditions Policy.
NeuroSense Therapeutics股價上漲，因該公司宣佈已啓動尋求在加拿大衛生部根據條件遵從通知政策下，爲PrimeC在ALS早期商業化獲批的過程。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間